Clinical Stage IV Cutaneous Melanoma AJCC v8 Clinical Trials

57 clinical trials for Clinical Stage IV Cutaneous Melanoma AJCC v8 across international registries, including 13 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study — RECRUITING · PHASE2
• Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer — RECRUITING · PHASE1
• Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer — RECRUITING · PHASE1
• Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer — RECRUITING · PHASE1
• Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma — RECRUITING · PHASE1
• Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors — RECRUITING · PHASE1
• Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types — RECRUITING
• Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain — RECRUITING · PHASE1
• Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program — RECRUITING · PHASE2
• IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors — RECRUITING · PHASE1
• Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases — RECRUITING · PHASE2
• Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial — RECRUITING · PHASE2
• A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases — RECRUITING · PHASE2
• Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery — ACTIVE_NOT_RECRUITING · PHASE3
• Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma — ACTIVE_NOT_RECRUITING · PHASE1
• Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma — TERMINATED · PHASE2
• Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma — ACTIVE_NOT_RECRUITING · PHASE3
• A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma — ACTIVE_NOT_RECRUITING · PHASE2
• Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers — ACTIVE_NOT_RECRUITING · PHASE1
• Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial — ACTIVE_NOT_RECRUITING · PHASE2
• Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 — ACTIVE_NOT_RECRUITING · PHASE1
• The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors — SUSPENDED · PHASE1
• Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease — ACTIVE_NOT_RECRUITING · PHASE1
• Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases — ACTIVE_NOT_RECRUITING · PHASE2
• Circadian-Optimized Light Therapy for the Treatment of Patients With Advanced Melanoma Receiving Tumor-Infiltrating Lymphocyte Therapy — NOT_YET_RECRUITING · PHASE1
• Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV — ACTIVE_NOT_RECRUITING · PHASE1
• Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic Kidney Cancer — SUSPENDED · NA
• Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial — NOT_YET_RECRUITING · PHASE2
• Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies — TERMINATED · PHASE1
• Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma — COMPLETED · PHASE2
• Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors — ACTIVE_NOT_RECRUITING · PHASE2
• Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases — TERMINATED · PHASE1
• Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment — ACTIVE_NOT_RECRUITING · PHASE1
• Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases — TERMINATED · PHASE1
• Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma — ACTIVE_NOT_RECRUITING · PHASE2
• Stereotactic Radiosurgery in Treating Patients With Greater Than 3 Melanoma Brain Metastases — ACTIVE_NOT_RECRUITING · PHASE2
• Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy — ACTIVE_NOT_RECRUITING · PHASE2
• Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma — TERMINATED · PHASE1
• Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain — COMPLETED · PHASE2
• E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma — TERMINATED · PHASE1
• Bone Loss in Melanoma Survivors Receiving Immunotherapy — TERMINATED
• 7T MRI Scan for the Early Detection of Melanoma Brain Metastases — TERMINATED · NA
• Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung — WITHDRAWN · PHASE1
• Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies — TERMINATED · PHASE1
• Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma — COMPLETED · PHASE2
• Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma — TERMINATED · PHASE1
• Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma — TERMINATED · PHASE2
• Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer — COMPLETED · PHASE1

Refine this search